On August 11, 2022, the Shengbai Oral Liquid (Mixture) Bone Marrow Suppression Summit Forum · Shanxi Station was held on the cloud. The participants were well-known experts in the field of malignant tumor diagnosis and treatment from Beijing and Shanxi. The meeting carried out rich discussions on the thinking of integrating traditional Chinese and Western medicine in the diagnosis and treatment of malignant tumors, and the effectiveness of Shengbai oral liquid (mixture) in clinical application. Professor Liu Shuo from Guang'anmen Hospital of China Academy of Chinese Medical Sciences reported the results of pre-clinical research and RCT evaluation after marketing, so that the participating experts had a deep understanding of the effectiveness and safety of the product. Professor Ma Kai from Jincheng People's Hospital highly affirmed the effectiveness of Shengbai Oral Liquid (Mixture) in clinical application, emphasizing that Shengbai Oral Liquid (Mixture) not only increases white blood cells, but also fundamentally improves bone marrow hematopoiesis Function. Professor Xue Dong from Peking University Cancer Hospital finally made a summary of this meeting. With my country's emphasis on the treatment of malignant tumors with integrated traditional Chinese and Western medicine, traditional Chinese medicine is facing unprecedented opportunities and challenges. Under such circumstances, everyone should work together to discuss new ideas for the diagnosis and treatment of malignant tumors with the combination of traditional Chinese and Western medicine.

The conference was a complete success, and Mengyang Pharmaceutical will continue to work hard and continue to make contributions to improving the standardization level of Chinese and Western medicine in the treatment of malignant tumors in my country!

How to use Shengbai? Watch Beijing Shengbai Oral Liquid Clinical Practice Academic Forum

On August 13, 2022, the meeting kicked off with the welcome speech of the chairman of the conference, Professor Sun Tao of Beijing Oriental Hospital. The participating experts are from Beijing Cancer Hospital, Beijing Hospital of Traditional Chinese Medicine, Beijing Daxing People's Hospital and Fangshan First Hospital. At the meeting, many experts in traditional Chinese medicine, western medicine, internal medicine, and surgery discussed the advantages of Shengbai Oral Liquid and shared their experiences. At the same time, combined with the experience exchange of typical clinical cases, experts highly recognized the clinical value of Shengbai Oral Liquid, which plays an important role in the treatment of leukopenia caused by tumor radiotherapy and chemotherapy, and plays a major role in immune regulation. The meeting came to a successful conclusion in active and heated discussions. Professor Sun Tao, the chairman of the meeting, made a summary and gave full affirmation to this meeting. He hoped to discuss and communicate with many Chinese and Western medicine experts in the future. Mengyang Pharmaceutical will continue to work hard in the field of tumor treatment to benefit more patients and continuously improve their quality of life!

Feeling Love in Jinling—Symposium on Clinical Advantages of Shengbai Oral Liquid

The furnace of Jinling continues to heat up. On August 13, 2022, a seminar on the clinical advantages of Shengbai Oral Liquid was successfully held in Nanjing, Jiangsu. The participating experts came from the General Hospital of the Eastern Theater Command and the Eighth First Hospital of the People’s Liberation Army. The mechanism of action, effectiveness and advantages of clinical application. Through the discussion of evidence-based evidence and typical cases, the experts shared their experience in combination with long-term clinical experience, and further confirmed that Shengbai Oral Liquid is used in the treatment of leukopenia after chemotherapy and radiotherapy of malignant tumors. The mechanism of action is clear and the clinical curative effect is definite. . At the same time, during the discussion on the significant curative effect of Shengbai Oral Liquid on patients with cancer-related fatigue, the participating experts actively shared their views, and the atmosphere was very enthusiastic.

At the end of the meeting, Professor Sun Qian made a summary of the meeting, expressed her expectations for Shengbai Oral Liquid, and encouraged our company to make persistent efforts to benefit more patients. The meeting was a complete success. Mengyang Pharmaceutical will also keep its mission in mind, aiming to improve the quality of life of cancer patients and bring better treatment to more patients!

Shengbai Oral Liquid (Mixture) Clinical Practice Academic Forum Arrives in Hebei

On August 23, 2022, the Practical Forum on Clinical Application Advantages of Shengbai Oral Liquid (Mixture) - Hebei Station was successfully held in Tangshan City, Hebei Province. The participating experts are from the Affiliated Hospital of North China University of Science and Technology and the Fengrun District People's Hospital, including the Department of Oncology, Oncology, and Radiotherapy. They discussed the theory and practical experience of Shengbai Oral Liquid (Mixture) in clinical practice. A comprehensive multidisciplinary discussion on the diagnosis and treatment of malignant tumors, discussing the practical experience of the clinical application of Shengbai Oral Liquid (mixture) in the process of surgery, radiotherapy, and chemotherapy. Professor Pang Dequan from the Affiliated Hospital of North China University of Science and Technology brought a lot of surprises to the participating experts with his narration on the mechanism and practical application of Shengbai Oral Liquid (mixture) in the radiotherapy department, especially in the whole application of accompanying radiotherapy and clinical efficacy. recognized. Professor Wang Xiaojing from Fengrun District People's Hospital finally made a summary of this meeting—unique advantages, multi-disciplinary coverage and application, everything is patient-centered, all-round prevention and treatment of leukopenia, and treatment of cancer-related fatigue, improving the quality of life of patients is inevitable. It will make Shengbai oral liquid (mixture) shine in the clinical application process.